KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Bristol Myers Squibb (BMY) over the last 13 years, with Q3 2025 value amounting to $225.0 million.

  • Bristol Myers Squibb's Non-Current Deferred Tax Liability fell 4767.44% to $225.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.0 million, marking a year-over-year decrease of 4767.44%. This contributed to the annual value of $369.0 million for FY2024, which is 9247.55% down from last year.
  • Bristol Myers Squibb's Non-Current Deferred Tax Liability amounted to $225.0 million in Q3 2025, which was down 4767.44% from $247.0 million recorded in Q2 2025.
  • Bristol Myers Squibb's Non-Current Deferred Tax Liability's 5-year high stood at $5.8 billion during Q4 2021, with a 5-year trough of $225.0 million in Q3 2025.
  • For the 5-year period, Bristol Myers Squibb's Non-Current Deferred Tax Liability averaged around $2.4 billion, with its median value being $1.6 billion (2023).
  • Over the last 5 years, Bristol Myers Squibb's Non-Current Deferred Tax Liability had its largest YoY gain of 776.94% in 2024, and its largest YoY loss of 9247.55% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Non-Current Deferred Tax Liability stood at $5.8 billion in 2021, then decreased by 13.74% to $5.0 billion in 2022, then decreased by 1.27% to $4.9 billion in 2023, then tumbled by 92.48% to $369.0 million in 2024, then tumbled by 39.02% to $225.0 million in 2025.
  • Its last three reported values are $225.0 million in Q3 2025, $247.0 million for Q2 2025, and $276.0 million during Q1 2025.